Get started
Author

Kateřina Kopečková

Observed names: K Kopeckova, K. KOPECKOVA, K. Kopeckova, K. Kopečková, KATERINA KOPECKOVA, Katerina Kopeckova, Katerina Kopečková, Kateřina Kopečkova, Kopeckova K, Kopeckova, K., Kopeckova, Katerina
Observed institutions: University of Pisa, The University of Sydney, Thomas Jefferson University, Universidade de São Paulo, Charles University, Heidelberg University, Region Zealand, Hospital de Sant Pau, Institut Gustave Roussy, Zealand University Hospital, University Hospital in Motol, Centre François Baclesse, Tianjin Medical University
ORCID: 0000-0002-1907-163X
Observed ORCID: 0000-0002-1907-163X
OpenAlex ID: A5036367652
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 · P.G. Casali, N. Abecassis, et al. · Annals of Oncology · 1,615
PDF
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
2021 · A. Gronchi, A.B. Miah, et al. · Annals of Oncology · 1,075
PDF
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 · P.G. Casali, N. Abecassis, et al. · Annals of Oncology · 750
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 · P.G. Casali, S. Bielack, et al. · Annals of Oncology · 616
PDF
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
2021 · P.G. Casali, J.Y. Blay, et al. · Annals of Oncology · 615
PDF
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
2021 · S.J. Strauss, A.M. Frezza, et al. · Annals of Oncology · 494
PDF
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
2017 · B. Kasper, C. Baumgarten, et al. · Annals of Oncology · 422
PDF
Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer
2023 · Julien Hadoux, Rossella Elisei, et al. · New England Journal of Medicine · 213
Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”
2018 · P.G. Casali, N. Abecassis, et al. · Annals of Oncology · 210
PDF
Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”
2018 · P.G. Casali, N. Abecassis, et al. · Annals of Oncology · 187
PDF
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
2018 · P G Casali, N Abecassis, et al. · PubMed · 117
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’
2020 · Patrick Schöffski, Olivier Mir, et al. · European Journal of Cancer · 72
Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study
2017 · Young Soo Rho, Marine Gilabert, et al. · Clinical Colorectal Cancer · 67
Nanodrugs used in cancer therapy
2019 · Katerina Kopeckova, Tomas Eckschlager, et al. · Biomedical Papers · 59
PDF
European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN
2021 · J.-Y. Blay, P. Casali, et al. · ESMO Open · 40
PDF
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe
2018 · Eduard Vrdoljak, Gyorgy Bodoky, et al. · The Oncologist · 35
PDF
Plasma oxysterol levels in luminal subtype breast cancer patients are associated with clinical data
2019 · Alzbeta Kloudova-Spalenkova, Yune-Fang Ueng, et al. · The Journal of Steroid Biochemistry and Molecular Biology · 34
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
2025 · Lorenzo Falchi, Marcel Nijland, et al. · The Lancet · 33
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
2018 · Ian Chau, Joon Oh Park, et al. · British Journal of Cancer · 33
PDF
Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response
2020 · Viktor Hlaváč, Radka Václavíková, et al. · International Journal of Molecular Sciences · 28
PDF
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
2020 · Christian Rolfo, Nicolas Isambert, et al. · British Journal of Clinical Pharmacology · 25
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
2023 · David Belada, Katerina Kopeckova, et al. · Blood · 22
PDF
Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry
2016 · Katerina Kopeckova, Tomas Buchler, et al. · Targeted Oncology · 22
Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response
2021 · Viktor Hlaváč, Radka Václavíková, et al. · International Journal of Molecular Sciences · 20
PDF
Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation
2019 · Radek Indra, Petr Pompach, et al. · International Journal of Molecular Sciences · 20
PDF
Works count: 115
Citation count: 7,176
H-index: 22
I10-index: 41
Year
Topic
Type